At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 100 enrolled
Drug / intervention
Glucagondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of Glucagon in Outpatient Colonoscopy? A Prospective Double-Blind Randomized Controlled Trial
In Brief
A Phase 4 clinical trial evaluating Glucagon for Colon Cancer. Completed, enrolled 100 participants across 1 site.
Detailed Summary
The investigators believe that glucagon therapy will have a positive impact on key parameters of colonoscopy such as cecal intubation time, withdrawal time, total procedure time, adenoma detection rate, endoscopist's assessment of the difficulty of the procedure, patient comfort, and patient's willingness to undergo a repeat colonoscopy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColon Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartApr 2014
Primary CompletionMay 2018
TodayJul 2026
First PostedMar 5, 2014
Enrollment StartApr 1, 2014
Primary CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.3 years ago
Interventions
Glucagondrug
glucagon (hormone produced by the body) administered through IV